• Scam Diego alerts

Biotech La Jolla Pharmaceutical stock is down a whopping 91.42 percent this morning (Feb. 12) to 19.8 cents -- quite a half-day plunge. The company said it would stop developing its lead drug candidate, an experimental treatment for lupus. An efficacy analysis showed negative results. One analyst says La Jolla's cash may only last until May. The experimental drug, Riquent, was the company's only clinical-stage drug candidate, according to Reuters. La Jolla was developing it with another firm, BioMarin Pharmaceutical.

  • Scam Diego alerts

Comments

Sign in to comment

Win a pair of VIP tickets to
Reader Tacotopia!

Join our newsletter list

Each newsletter subscription
means another chance to win!

Close